Homology Medicines Inc (NASDAQ:FIXX) CEO Arthur Tzianabos sold 12,500 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $20.50, for a total value of $256,250.00. Following the completion of the transaction, the chief executive officer now directly owns 90,005 shares in the company, valued at approximately $1,845,102.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Arthur Tzianabos also recently made the following trade(s):

  • On Monday, December 2nd, Arthur Tzianabos sold 12,500 shares of Homology Medicines stock. The stock was sold at an average price of $16.25, for a total value of $203,125.00.
  • On Friday, November 29th, Arthur Tzianabos sold 12,500 shares of Homology Medicines stock. The stock was sold at an average price of $16.04, for a total value of $200,500.00.

Homology Medicines stock opened at $18.69 on Monday. The business has a fifty day moving average of $18.37 and a two-hundred day moving average of $17.60. The firm has a market cap of $904.03 million, a P/E ratio of -9.35 and a beta of 0.30. Homology Medicines Inc has a twelve month low of $11.05 and a twelve month high of $31.80.

Homology Medicines (NASDAQ:FIXX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.09). The company had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $0.38 million. Homology Medicines had a negative return on equity of 43.33% and a negative net margin of 4,740.81%. Research analysts anticipate that Homology Medicines Inc will post -2.61 earnings per share for the current year.

Several research analysts recently issued reports on the company. Oppenheimer assumed coverage on Homology Medicines in a research note on Friday, November 1st. They issued a “market perform” rating on the stock. FIX assumed coverage on Homology Medicines in a research note on Thursday, October 31st. They issued a “market perform” rating on the stock. HC Wainwright set a $36.00 price objective on Homology Medicines and gave the stock a “buy” rating in a research note on Tuesday, September 24th. Robert W. Baird assumed coverage on Homology Medicines in a research note on Monday, September 9th. They issued an “outperform” rating and a $30.00 price objective on the stock. Finally, ValuEngine raised Homology Medicines from a “hold” rating to a “buy” rating in a research note on Friday. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Homology Medicines currently has a consensus rating of “Buy” and an average price target of $31.40.

A number of institutional investors have recently bought and sold shares of FIXX. Price T Rowe Associates Inc. MD lifted its holdings in Homology Medicines by 84.3% during the second quarter. Price T Rowe Associates Inc. MD now owns 1,957,184 shares of the company’s stock worth $38,302,000 after buying an additional 894,960 shares during the period. BlackRock Inc. lifted its holdings in Homology Medicines by 48.7% during the second quarter. BlackRock Inc. now owns 2,084,139 shares of the company’s stock worth $40,786,000 after buying an additional 682,665 shares during the period. Vanguard Group Inc. lifted its holdings in Homology Medicines by 53.9% during the second quarter. Vanguard Group Inc. now owns 1,016,124 shares of the company’s stock worth $19,886,000 after buying an additional 355,908 shares during the period. Cormorant Asset Management LP purchased a new stake in Homology Medicines during the second quarter worth $5,871,000. Finally, Point72 Asset Management L.P. purchased a new stake in Homology Medicines during the second quarter worth $3,996,000. Institutional investors own 73.71% of the company’s stock.

Homology Medicines Company Profile

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Recommended Story: Stock Symbol

Insider Buying and Selling by Quarter for Homology Medicines (NASDAQ:FIXX)

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.